Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle Fraser

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Movement Disorders : Official Journal of the Movement Disorder Society|December 13, 2025
LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's DiseaseAnthony E Lang, Robert A Hauser, Lorraine V Kalia, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 15, 2016
G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in NeuronsLaura A Volpicelli-Daley, Hisham Abdelmotilib, Zhiyong Liu, et al.
Neurology|February 5, 2024
Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical TrialR Matthew Hutchison, Kyle Fraser, Minhua Yang, et al.
ACS Nano|October 21, 2017
Integrated Kidney Exosome Analysis for the Detection of Kidney Transplant RejectionJongmin Park, Hsing-Ying Lin, Jean Pierre Assaker, et al.
The New England Journal of Medicine|August 3, 2022
Trial of Cinpanemab in Early Parkinson's DiseaseAnthony E Lang, Andrew D Siderowf, Eric A Macklin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 22, 2023
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's DiseaseDanna Jennings, Sarah Huntwork-Rodriguez, Maurits F J M Vissers, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Movement Disorders : Official Journal of the Movement Disorder Society|December 13, 2025
LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's DiseaseAnthony E Lang, Robert A Hauser, Lorraine V Kalia, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 15, 2016
G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in NeuronsLaura A Volpicelli-Daley, Hisham Abdelmotilib, Zhiyong Liu, et al.
Neurology|February 5, 2024
Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical TrialR Matthew Hutchison, Kyle Fraser, Minhua Yang, et al.
ACS Nano|October 21, 2017
Integrated Kidney Exosome Analysis for the Detection of Kidney Transplant RejectionJongmin Park, Hsing-Ying Lin, Jean Pierre Assaker, et al.
The New England Journal of Medicine|August 3, 2022
Trial of Cinpanemab in Early Parkinson's DiseaseAnthony E Lang, Andrew D Siderowf, Eric A Macklin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 22, 2023
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's DiseaseDanna Jennings, Sarah Huntwork-Rodriguez, Maurits F J M Vissers, et al.
Pageof 2